Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on July 7, 2025, discloses Haleon Plc's historic proforma category financial performance. The filing aligns with a strategic restructuring announced on May 1, 2025, effective for the 2025 Half Year Results. The company is transitioning to a six-category reporting structure: Oral Health; Vitamins, Minerals, and Supplements (VMS); Pain Relief; Respiratory Health; Digestive Health; and Therapeutic Skin Health and Other. Notable changes include splitting "Digestive Health & Other" into two distinct categories and moving "Smokers Health" from Digestive Health to Respiratory Health.
Key Financial Metrics
The filing provides restated revenue data for FY 2023, FY 2024, and Q1 2025 under the new category structure. Profit, cash flow, margins, debt, and liquidity metrics are not provided in this specific filing.
| Category | FY 2023 Revenue (£m) | FY 2024 Revenue (£m) | Q1 2025 Revenue (£m) | FY 2024 Org. Growth | Q1 2025 Org. Growth |
|---|---|---|---|---|---|
| Oral Health | 3,136 | 3,312 | 880 | 9.6% | 6.6% |
| VMS | 1,640 | 1,696 | 416 | 7.6% | 0.9% |
| Pain Relief | 2,652 | 2,564 | 661 | 0.1% | 2.6% |
| Respiratory Health | 2,244 | 2,122 | 525 | 1.0% | 0.7% |
| Digestive Health | 1,012 | 1,029 | 254 | 5.5% | 2.3% |
| Therapeutic Skin Health & Other | 618 | 510 | 117 | 9.8% | 10.4% |
| TOTAL | 11,302 | 11,233 | 2,853 | 5.0% | 3.5% |
Material Changes vs. Prior Period
- Revenue Trend: Total reported revenue declined slightly from £11,302m in FY 2023 to £11,233m in FY 2024 (-0.6%). Q1 2025 reported revenue was £2,853m, representing a -2.3% reported growth compared to Q1 2024.
- Organic Growth: Total organic revenue growth slowed from 8.0% in FY 2023 to 5.0% in FY 2024. Q1 2025 organic growth was 3.5%.
- Category Performance:
- Oral Health: Remains the largest category, showing consistent organic growth (9.6% FY 2024, 6.6% Q1 2025).
- Therapeutic Skin Health & Other: Reported revenue dropped significantly in FY 2024 (-17.5%) but showed strong organic growth of 10.4% in Q1 2025.
- Respiratory Health: Reported revenue declined -5.4% in FY 2024 and -11.0% in Q1 2025, though organic growth remained positive at 0.7% in Q1 2025.
- Pain Relief: Reported revenue declined -3.3% in FY 2024 but returned to positive organic growth of 2.6% in Q1 2025.
Guidance, Outlook, and Risks
The filing states the purpose of the reporting change is to better align with strategic opportunities and improve financial visibility. The company will begin reporting in this new structure at the 2025 Half Year Results on July 31, 2025. No specific forward-looking guidance, risk factors, or contingencies are detailed in this specific text excerpt beyond the structural changes.
Investor Verification Checklist
- Verify the impact of the new category structure on year-over-year comparability for the upcoming Half Year Results.
- Confirm the drivers behind the -17.5% reported revenue decline in "Therapeutic Skin Health and Other" in FY 2024 versus the 10.4% organic growth in Q1 2025.
- Review the full 2025 Half Year Results (July 31, 2025) for profit, cash flow, and margin data not included in this proforma revenue summary.
- Assess the sustainability of the 3.5% organic growth in Q1 2025 against the slowing trend seen in FY 2024 (5.0%).